

Angela Casini

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/7947029/publications.pdf](https://exaly.com/author-pdf/7947029/publications.pdf)

Version: 2025-02-01

259

PR articles

18,957

PR citations

5157

73

PR h-index

7593

135

g-index

276

documents

22652

doc citations

5765

78

h-index

17706

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Introducing Metal-Organic Frameworks to Melt Electrowriting: Multifunctional Scaffolds with Controlled Microarchitecture for Tissue Engineering Applications. <i>Advanced Functional Materials</i> , 2024, 34, .	17.0	24
2	Potent Anticancer Activity of a Dinuclear Gold(I) bis-N-Heterocyclic Imine Complex Related to Thioredoxin Reductase Inhibition <i>in Vitro</i> . <i>ChemPlusChem</i> , 2024, 89, .	2.7	7
3	Metals in Cancer Research: Beyond Platinum Metallodrugs. <i>ACS Central Science</i> , 2024, 10, 242-250.	9.2	92
4	A graft-to strategy of poly(vinylphosphonates) on dopazide-coated gold nanoparticles using <i>in situ</i> catalyst activation. <i>RSC Advances</i> , 2024, 14, 8145-8149.	4.4	3
5	(SiFA)SeFe: A Hydrophilic Silicon-Based Fluoride Acceptor Enabling Versatile Peptidic Radiohybrid Tracers. <i>Journal of Medicinal Chemistry</i> , 2024, 67, 14077-14094.	5.6	7
6	Assembling a new generation of radiopharmaceuticals with supramolecular theranostics. <i>Nature Reviews Chemistry</i> , 2024, 8, 893-914.	46.7	21
7	PET Imaging of Self-Assembled ¹⁸ F-Labelled Pd ₂ L ₄ Metallacages for Anticancer Drug Delivery. <i>Chemistry - A European Journal</i> , 2023, 29, .	3.4	19
8	Bioinorganic supramolecular coordination complexes and their biomedical applications. <i>FEBS Letters</i> , 2023, 597, 191-202.	2.7	35
9	Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	14.4	152
10	Elucidating the Multimodal Anticancer Mechanism of an Organometallic Terpyridine Platinum(II) N-Heterocyclic Carbene Complex against Triple-Negative Breast Cancer <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3995-4008.	5.6	24
11	Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems. <i>Angewandte Chemie</i> , 2023, 135, .	1.4	12
12	Organometallic Pillarplexes That Bind DNA 4-Way Holliday Junctions and Forks. <i>Journal of the American Chemical Society</i> , 2023, 145, 13570-13580.	15.0	23
13	Electrochemical Detection of Drugs via a Supramolecular Cucurbit[7]uril-Based Indicator Displacement Assay. <i>ACS Sensors</i> , 2023, 8, 2525-2532.	8.5	16
14	Exploring the Anticancer Activity of Tamoxifen-Based Metal Complexes Targeting Mitochondria. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 9823-9841.	5.6	35
15	Synthesis of ¹⁷⁷ Lu-Labeled, Somatostatin-2 Receptor-Targeted Metalla-Assemblies: Challenges in the Design of Supramolecular Radiotherapeutics. <i>Inorganic Chemistry</i> , 2023, 62, 20710-20720.	4.6	8
16	Application of Machine Learning Algorithms to Metadynamics for the Elucidation of the Binding Modes and Free Energy Landscape of Drug/Target Interactions: a Case Study. <i>Chemistry - A European Journal</i> , 2023, 29, .	3.4	10
17	Beyond Metal-Arenes: Monocarbonyl Ruthenium(II) Catalysts for Transfer Hydrogenation Reactions in Water and in Cells. <i>ACS Catalysis</i> , 2023, 13, 10798-10823.	12.4	16
18	Seeing the invisible: Preparative strategies to visualise elusive molecules using mass spectrometry imaging. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 168, 117304.	11.2	6

#	ARTICLE	IF	PR CITATIONS
19	Bio-based and bio-inspired adhesives from animals and plants for biomedical applications. <i>Materials Today Bio</i> , 2022, 13, 100203.	7.1	67
20	Aquaglyceroporin Modulators as Emergent Pharmacological Molecules for Human Diseases. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.6	20
21	Competitive profiling of ligandable cysteines in <i>Staphylococcus aureus</i> with an organogold compound. <i>Chemical Communications</i> , 2022, 58, 5526-5529.	3.4	21
22	Indenyl and Allyl Palladate Complexes Bearing N-Heterocyclic Carbene Ligands: an Easily Accessible Class of New Anticancer Drug Candidates. <i>European Journal of Inorganic Chemistry</i> , 2022, .	1.8	35
23	Highly-fluorescent BODIPY-functionalised metallocages as drug delivery systems: synthesis, characterisation and cellular accumulation studies. <i>Dalton Transactions</i> , 2022, 51, 7476-7490.	3.0	16
24	Cyclodextrin metal-organic frameworks and derivatives: recent developments and applications. <i>Chemical Society Reviews</i> , 2022, 51, 5175-5213.	37.8	144
25	Bottom-up Synthesis of Water-Soluble Gold Nanoparticles Stabilized by N-Heterocyclic Carbenes: From Structural Characterization to Applications. <i>Chemistry - A European Journal</i> , 2022, 28, .	3.4	28
26	Optimization of the Pharmacokinetic Profile of [99mTc]Tc-N4-Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence. <i>Pharmaceutics</i> , 2022, 15, 1133.	4.4	6
27	Dynamical Docking of Cyclic Dinuclear Au(I) Bis-N-heterocyclic Complexes Facilitates Their Binding to G-Quadruplexes. <i>Inorganic Chemistry</i> , 2022, 61, 20405-20423.	4.6	15
28	Identifying and validating the presence of Guanine-Quadruplexes (G4) within the blood fluke parasite <i>Schistosoma mansoni</i> . <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008770.	3.1	7
29	N-Heterocyclic carbenes as smart-gold nanoparticle stabilizers: State-of-the art and perspectives for biomedical applications. <i>Journal of Organometallic Chemistry</i> , 2021, 938, 121743.	2.1	34
30	Therapeutic potential of a copper complex loaded in pH-sensitive long circulating liposomes for colon cancer management. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120463.	4.8	49
31	Interfering with Metabolic Profile of Triple-Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. <i>Angewandte Chemie</i> , 2021, 133, 13517-13525.	1.4	3
32	The Beauty of Gold: Knowledge of Mechanisms Leads to Different Applications of Organogold Compounds in Medicine and Catalysis. <i>Chemistry Letters</i> , 2021, 50, 1516-1522.	1.1	14
33	Interfering with Metabolic Profile of Triple-Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 13405-13413.	14.4	64
34	Host-Guest Interactions in a Metal-Organic Framework Isoreticular Series for Molecular Photocatalytic CO ₂ Reduction. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 17854-17860.	14.4	119
35	An Organogold Compound as Potential Antimicrobial Agent against Drug-Resistant Bacteria: Initial Mechanistic Insights. <i>ChemMedChem</i> , 2021, 16, 3060-3070.	3.1	36
36	Investigation of Solvatomorphism and Its Photophysical Implications for Archetypal Trinuclear Au ₃ (1-Methylimidazolate) ₃ . <i>Molecules</i> , 2021, 26, 4404.	4.3	1

#	ARTICLE	IF	PR CITATIONS
37	C ¹³ C Cross-Couplings from a Cyclometalated Au(III) CN Complex: Mechanistic Insights and Synthetic Developments. <i>Chemistry - A European Journal</i> , 2021, 27, 14322-14334.	3.4	11
38	Mechanisms of irreversible aquaporin-10 inhibition by organogold compounds studied by combined biophysical methods and atomistic simulations. <i>Metallomics</i> , 2021, 13, .	2.6	8
39	Bioconjugate Supramolecular Pd ²⁺ Metallacages Penetrate the Blood Brain Barrier <i>In Vitro</i> and <i>In Vivo</i> . <i>Bioconjugate Chemistry</i> , 2021, 32, 1399-1408.	3.9	47
40	Comparative biological evaluation and G-quadruplex interaction studies of two new families of organometallic gold(I) complexes featuring N-heterocyclic carbene and alkynyl ligands. <i>Journal of Inorganic Biochemistry</i> , 2020, 202, 110844.	3.0	49
41	Exploring the Reactivity and Biological Effects of Heteroleptic N-Heterocyclic Carbene Gold(I)-Alkynyl Complexes. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 1040-1051.	1.8	42
42	Human red blood cell uptake and sequestration of arsenite and selenite: Evidence of seleno-bis(S-glutathionyl) arsinium ion formation in human cells. <i>Biochemical Pharmacology</i> , 2020, 180, 114141.	5.2	10
43	Insights into the Selectivity Mechanisms of Grapevine NIP Aquaporins. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6697.	4.5	13
44	Comparing the Antileishmanial Activity of Gold(I) and Gold(III) Compounds in <i>L. amazonensis</i> and <i>L. braziliensis</i> <i>In Vitro</i> . <i>ChemMedChem</i> , 2020, 15, 2146-2150.	3.1	38
45	An Organometallic Gold(I) Bis-N-Heterocyclic Carbene Complex with Multimodal Activity in Ovarian Cancer Cells. <i>Chemistry - A European Journal</i> , 2020, 26, 15528-15537.	3.4	63
46	Exploring the Chemoselectivity towards Cysteine Arylation by Cyclometallated Au ^{III} Compounds: New Mechanistic Insights. <i>ChemBioChem</i> , 2020, 21, 3071-3076.	2.6	31
47	Gold compounds for catalysis and metal-mediated transformations in biological systems. <i>Current Opinion in Chemical Biology</i> , 2020, 55, 103-110.	5.9	59
48	Glutathione-responsive cyclodextrin-nanosponges as drug delivery systems for doxorubicin: Evaluation of toxicity and transport mechanisms in the liver. <i>Toxicology in Vitro</i> , 2020, 65, 104800.	2.7	45
49	Carbon-Phosphorus Coupling from C ¹³ N Cyclometalated Au ^{III} Complexes. <i>Chemistry - A European Journal</i> , 2020, 26, 4226-4231.	3.4	24
50	Design Strategies and Medicinal Applications of Metal-Peptidic Bioconjugates. <i>Bioconjugate Chemistry</i> , 2020, 31, 1279-1288.	3.9	52
51	Targeted imaging of integrins in cancer tissues using photocleavable Ru(II) polypyridine complexes as mass-tags. <i>Chemical Communications</i> , 2020, 56, 5941-5944.	3.4	18
52	Aquaporin-3 is involved in NLRP3-inflammasome activation contributing to the setting of inflammatory response. <i>Cellular and Molecular Life Sciences</i> , 2020, 78, 3073-3085.	5.6	46
53	Aquaporin-driven hydrogen peroxide transport: a case of molecular mimicry?. <i>RSC Chemical Biology</i> , 2020, 1, 390-394.	3.3	26
54	Highly luminescent metallacages featuring bispyridyl ligands functionalised with BODIPY for imaging in cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2019, 199, 110781.	3.0	31

#	ARTICLE	IF	PR CITATIONS
55	<i>In My Element</i>: Gold. Chemistry - A European Journal, 2019, 25, 12234-12234.	3.4	1
56	The antifibrotic potential of a sustained release formulation of a PDGF β -receptor targeted rho kinase inhibitor. Journal of Controlled Release, 2019, 296, 250-257.	11.1	20
57	Recent Developments of Supramolecular Metal-based Structures for Applications in Cancer Therapy and Imaging. Theranostics, 2019, 9, 3150-3169.	11.5	172
58	Unveiling the Mechanisms of Aquaglyceroporin β Water and Glycerol Permeation by Metadynamics. Chemistry - A European Journal, 2019, 25, 8713-8718.	3.4	21
59	Sperm selection with density gradient centrifugation and swim up: effect on DNA fragmentation in viable spermatozoa. Scientific Reports, 2019, 9, .	3.5	115
60	Cyclometalated Au ^{III} Complexes for Cysteine Arylation in Zinc Finger Protein Domains: towards Controlled Reductive Elimination. Chemistry - A European Journal, 2019, 25, 7628-7634.	3.4	66
61	Exo-Functionalized Metallacages as Host-Guest Systems for the Anticancer Drug Cisplatin. Frontiers in Chemistry, 2019, 7, .	3.6	22
62	Copper Complex Nanoformulations Featuring Highly Promising Therapeutic Potential in Murine Melanoma Models. Nanomedicine, 2019, 14, 835-850.	3.1	50
63	Mediterranean, but not lacto-ovo-vegetarian, diet positively influence circulating progenitor cells for cardiovascular prevention: The CARDIVEG study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 604-610.	3.4	8
64	Ex vivo toxicological evaluation of experimental anticancer gold(i) complexes with lansoprazole-type ligands. Toxicology Research, 2019, 8, 885-895.	2.2	11
65	Effects of a 3-month dietary intervention with a lacto-ovo-vegetarian diet on vitamin B12 levels in a group of omnivores: results from the CARDIVEG (Cardiovascular Prevention with Vegetarian Diet) study. British Journal of Nutrition, 2019, 121, 756-762.	2.5	2
66	Imaging of protein distribution in tissues using mass spectrometry: An interdisciplinary challenge. TrAC - Trends in Analytical Chemistry, 2019, 112, 13-28.	11.2	49
67	Inhibition Mechanism of Urease by Au(III) Compounds Unveiled by X-ray Diffraction Analysis. ACS Medicinal Chemistry Letters, 2019, 10, 564-570.	3.4	35
68	Insights into the Mechanisms of Aquaporin-3 Inhibition by Gold(III) Complexes: the Importance of Non-Coordination Adduct Formation. Inorganic Chemistry, 2019, 58, 2140-2148.	4.6	36
69	Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. ChemMedChem, 2018, 13, 1131-1145.	3.1	28
70	Selective targeting of PARP-1 zinc finger recognition domains with Au(^{III}) organometallics. Chemical Communications, 2018, 54, 611-614.	3.4	51
71	Gold(III) Pyridine-Benzimidazole Complexes as Aquaglyceroporin Inhibitors and Antiproliferative Agents. Inorganics, 2018, 6, 123.	2.8	15
72	Molecular Basis of Aquaporin-7 Permeability Regulation by pH. Cells, 2018, 7, 207.	4.8	36

#	ARTICLE	IF	PR CITATIONS
73	New Variations on the Theme of Gold(III) C ¹ N ² Cyclometalated Complexes as Anticancer Agents: Synthesis and Biological Characterization. <i>Inorganic Chemistry</i> , 2018, 57, 14852-14865.	4.6	35
74	Relevance of Copper and Organic Cation Transporters in the Activity and Transport Mechanisms of an Anticancer Cyclometalated Gold(III) Compound in Comparison to Cisplatin. <i>Frontiers in Chemistry</i> , 2018, 6, .	3.6	21
75	Bioconjugation of Supramolecular Metallacages to Integrin Ligands for Targeted Delivery of Cisplatin. <i>Bioconjugate Chemistry</i> , 2018, 29, 3856-3865.	3.9	54
76	Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents. <i>Metallomics</i> , 2018, 10, 696-712.	2.6	66
77	On the Mechanism of Gold/NHC Compounds Binding to DNA G-Quadruplexes: Combined Metadynamics and Biophysical Methods. <i>Angewandte Chemie</i> , 2018, 130, 14732-14736.	1.4	16
78	On the Mechanism of Gold/NHC Compounds Binding to DNA G-Quadruplexes: Combined Metadynamics and Biophysical Methods. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 14524-14528.	14.4	69
79	Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives. <i>Current Medicinal Chemistry</i> , 2018, 25, 437-461.	2.6	65
80	Bioconjugation strategies to couple supramolecular exo-functionalized palladium cages to peptides for biomedical applications. <i>Chemical Communications</i> , 2017, 53, 1405-1408.	3.4	38
81	Nonconventional <i>trans</i> -Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytotoxicity Studies. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1835-1840.	1.8	11
82	Mass spectrometry as a powerful tool to study therapeutic metallodrugs speciation mechanisms: Current frontiers and perspectives. <i>Coordination Chemistry Reviews</i> , 2017, 352, 432-460.	23.2	110
83	The mechanism of aquaporin inhibition by gold compounds elucidated by biophysical and computational methods. <i>Chemical Communications</i> , 2017, 53, 3830-3833.	3.4	54
84	Mechanistic Insights into Gold Organometallic Compounds and their Biomedical Applications. <i>Chimia</i> , 2017, 71, 92.	0.8	38
85	A Potent Tartrate Resistant Acid Phosphatase Inhibitor to Study the Function of TRAP in Alveolar Macrophages. <i>Scientific Reports</i> , 2017, 7, .	3.5	23
86	A Multi-Level Theoretical Study to Disclose the Binding Mechanisms of Gold(III)-Bipyridyl Compounds as Selective Aquaglyceroporin Inhibitors. <i>Chemistry - A European Journal</i> , 2017, 23, 13802-13813.	3.4	34
87	Exploring the C ¹ N ² C theme: Synthesis and biological properties of tridentate cyclometalated gold(III) complexes. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5452-5460.	2.6	37
88	On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent. <i>Metallomics</i> , 2017, 9, 1786-1795.	2.6	25
89	Characterization of Hydrophilic Gold(I) N-Heterocyclic Carbene (NHC) Complexes as Potent TrxR Inhibitors Using Biochemical and Mass Spectrometric Approaches. <i>Inorganic Chemistry</i> , 2017, 56, 14237-14250.	4.6	99
90	Functionalization of Ruthenium(II) Terpyridine Complexes with Cyclic RGD Peptides To Target Integrin Receptors in Cancer Cells. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1667-1672.	1.8	27

#	ARTICLE	IF	PR CITATIONS
91	Aquaporin modulators: a patent review (2010–2015). Expert Opinion on Therapeutic Patents, 2017, 27, 49-62.	4.0	55
92	Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. European Journal of Clinical Nutrition, 2017, 72, 30-43.	2.8	846
93	Anticancer Gold κ^2 -Heterocyclic Carbene Complexes: A Comparative in vitro and ex vivo Study. ChemMedChem, 2017, 12, 1429-1435.	3.1	60
94	Nanoformulations of a Potent copper-based Aquaporin Inhibitor With Cytotoxic Effect Against Cancer Cells. Nanomedicine, 2016, 11, 1817-1830.	3.1	57
95	Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. Journal of Inorganic Biochemistry, 2016, 163, 318-322.	3.0	5
96	Evaluation of New Palladium Cages as Potential Delivery Systems for the Anticancer Drug Cisplatin. Chemistry - A European Journal, 2016, 22, 2253-2256.	3.4	140
97	Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation. Angewandte Chemie, 2016, 128, 4328-4331.	1.4	47
98	Supramolecular exo-functionalized palladium cages: fluorescent properties and biological activity. Dalton Transactions, 2016, 45, 8556-8565.	3.0	54
99	Toward anticancer gold-based compounds targeting PARP-1: a new case study. RSC Advances, 2016, 6, 79147-79152.	4.4	13
100	Self-Assembled Palladium and Platinum Coordination Cages: Photophysical Studies and Anticancer Activity. European Journal of Inorganic Chemistry, 2016, 2016, 5189-5196.	1.8	52
101	Self-assembly of highly luminescent heteronuclear coordination cages. Dalton Transactions, 2016, 45, 12297-12300.	3.0	52
102	Transition-metal norharmone compounds as possible cytotoxic agents: New insights based on a coordination chemistry perspective. Journal of Inorganic Biochemistry, 2016, 165, 128-135.	3.0	27
103	Ferrocenyl-Coupled κ^2 -Heterocyclic Carbene Complexes of Gold(I): A Successful Approach to Multinuclear Anticancer Drugs. Chemistry - A European Journal, 2016, 22, 18953-18962.	3.4	73
104	Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation. Angewandte Chemie - International Edition, 2016, 55, 4256-4259.	14.4	96
105	New Luminescent Polynuclear Metal Complexes with Anticancer Properties: Toward Structure-Activity Relationships. Inorganic Chemistry, 2016, 55, 2544-2557.	4.6	75
106	Mass Spectrometry Uncovers Molecular Reactivities of Coordination and Organometallic Gold(III) Drug Candidates in Competitive Experiments That Correlate with Their Biological Effects. Inorganic Chemistry, 2016, 55, 4248-4259.	4.6	56
107	Structure and biological activities of metal complexes of flumequine. RSC Advances, 2016, 6, 19555-19570.	4.4	27
108	Exploring the gating mechanisms of aquaporin-3: new clues for the design of inhibitors?. Molecular BioSystems, 2016, 12, 1564-1573.	3.2	36

#	ARTICLE	IF	PR CITATIONS
109	The inhibition of glycerol permeation through aquaglyceroporin-3 induced by mercury(II): A molecular dynamics study. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 78-84.	3.0	29
110	Exploring the potential of gold(III) cyclometallated compounds as cytotoxic agents: variations on the C ^N theme. <i>Dalton Transactions</i> , 2015, 44, 11911-11918.	3.0	68
111	Improved Synthesis of <i>N</i> -Benzylaminoferrocene-Based Prodrugs and Evaluation of Their Toxicity and Antileukemic Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2015-2024.	5.6	82
112	Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 1005-1020.	2.5	106
113	Correlation between the Stereochemistry and Bioactivity in Octahedral Rhodium Prolinato Complexes. <i>Inorganic Chemistry</i> , 2015, 54, 8111-8120.	4.6	17
114	Adjusting the DNA Interaction and Anticancer Activity of Pt(II) N-Heterocyclic Carbene Complexes by Steric Shielding of the Trans Leaving Group. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6283-6292.	5.6	82
115	Reactivity of Cys4 Zinc Finger Domains with Gold(III) Complexes: Insights into the Formation of Gold Fingers. <i>Inorganic Chemistry</i> , 2015, 54, 4104-4113.	4.6	41
116	Gold finger formation studied by high-resolution mass spectrometry and in silico methods. <i>Chemical Communications</i> , 2015, 51, 1612-1615.	3.4	44
117	Insights into the strong in-vitro anticancer effects for bis(triphenylphosphane)iminium compounds having perchlorate, tetrafluoroborate and bis(chlorido)argentate anions. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 346-354.	3.0	14
118	Gold(I) N-heterocyclic carbene complexes with an activable ester moiety: Possible biological applications. <i>Journal of Organometallic Chemistry</i> , 2015, 775, 124-129.	2.1	39
119	A Gold Coordination Compound as a Chemical Probe to Unravel Aquaporin ⁷ Function. <i>ChemBioChem</i> , 2014, 15, 1487-1494.	2.6	43
120	Functional Inhibition of Aquaporin-3 With a Gold-Based Compound Induces Blockage of Cell Proliferation. <i>Journal of Cellular Physiology</i> , 2014, 229, 1787-1801.	4.2	67
121	Cytotoxic Gold(I) N-heterocyclic Carbene Complexes with Phosphane Ligands as Potent Enzyme Inhibitors. <i>ChemMedChem</i> , 2014, 9, 1205-1210.	3.1	83
122	Self-assembled M2L4 coordination cages: Synthesis and potential applications. <i>Coordination Chemistry Reviews</i> , 2014, 275, 19-36.	23.2	241
123	Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial hot spots for protein-protein recognition. <i>Journal of Inorganic Biochemistry</i> , 2014, 135, 58-67.	3.0	11
124	Caffeine-Based Gold(I) <i>N</i> -Heterocyclic Carbenes as Possible Anticancer Agents: Synthesis and Biological Properties. <i>Inorganic Chemistry</i> , 2014, 53, 2296-2303.	4.6	230
125	Gold(III) compounds with lansoprazole-type ligands: synthesis, characterization and anticancer properties in vitro. <i>MedChemComm</i> , 2014, 5, 1418-1422.	4.6	11
126	Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents. <i>Inorganic Chemistry Frontiers</i> , 2014, 1, 231-241.	6.4	48

#	ARTICLE	IF	PR CITATIONS
127	New Gold(I) Organometallic Compounds with Biological Activity in Cancer Cells. <i>European Journal of Inorganic Chemistry</i> , 2014, 2014, 4532-4536.	1.8	87
128	Gold compounds as aquaporin inhibitors: new opportunities for therapy and imaging. <i>MedChemComm</i> , 2014, 5, 1444-1453.	4.6	38
129	New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: Are two metals better than one?. <i>Journal of Inorganic Biochemistry</i> , 2014, 141, 10-16.	3.0	70
130	Light-stable bis(norharmine)silver(I) compounds: Synthesis, characterization and antiproliferative effects in cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2014, 140, 1-5.	3.0	29
131	Re(VII) and Tc(VII) trioxo complexes stabilized by tridentate ligands and their potential use as radiopharmaceuticals. <i>Coordination Chemistry Reviews</i> , 2014, 276, 97-111.	23.2	22
132	Cellular Transport Mechanisms of Cytotoxic Metallodrugs: An Overview beyond Cisplatin. <i>Molecules</i> , 2014, 19, 15584-15610.	4.3	176
133	Aquaporin Inhibition by Gold(III) Compounds: New Insights. <i>ChemMedChem</i> , 2013, 8, 1086-1092.	3.1	85
134	A new target for gold(I) compounds: Glutathione-S-transferase inhibition by auranofin. <i>Journal of Inorganic Biochemistry</i> , 2013, 119, 38-42.	3.0	48
135	BODIPY-phosphane as a versatile tool for easy access to new metal-based theranostics. <i>Dalton Transactions</i> , 2013, 42, 6102-6109.	3.0	57
136	Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights. <i>Metallomics</i> , 2013, 5, 1006.	2.6	130
137	Emerging protein targets for metal-based pharmaceutical agents: An update. <i>Coordination Chemistry Reviews</i> , 2013, 257, 2689-2704.	23.2	138
138	Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. <i>Chemical Society Reviews</i> , 2013, 42, 6186.	37.8	146
139	Potential Anticancer Heterometallic Fe-Au and Fe-Pd Agents: Initial Mechanistic Insights. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5806-5818.	5.6	93
140	The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. <i>Journal of Inorganic Biochemistry</i> , 2013, 118, 94-99.	3.0	38
141	The Formation of Oxytocin Dimers is Suppressed by the Zinc-Aspartate-Oxytocin Complex. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 1734-1741.	3.2	16
142	Influence of the π -coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. <i>Frontiers in Chemistry</i> , 2013, 1, .	3.6	27
143	Next-Generation Anticancer Metallodrugs. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 219-235.	3.0	203
144	Gold(I) Carbene Complexes Causing Thioredoxin $>1</math> and Thioredoxin >2</math> Oxidation as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2012, 55, 5518-5528.$	5.6	244

#	ARTICLE	IF	PR CITATIONS
145	Reactivity and Biological Properties of a Series of Cytotoxic Pt ₂ (amine) ₂ Complexes, Either <i>cis</i> or <i>trans</i> Configured. <i>Inorganic Chemistry</i> , 2012, 51, 1717-1726.	4.6	39
146	Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1. <i>Dalton Transactions</i> , 2012, 41, 3287.	3.0	65
147	Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry?. <i>Chemical Science</i> , 2012, 3, 3135.	7.1	183
148	Exploring the mechanisms of metal-based pharmacological agents via an integrated approach. <i>Journal of Inorganic Biochemistry</i> , 2012, 109, 97-106.	3.0	45
149	Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound. <i>PLoS ONE</i> , 2012, 7, e37435.	2.4	122
150	Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(III) compounds studied with combined mass spectrometry and biochemical assays. <i>MedChemComm</i> , 2011, 2, 50-54.	4.6	104
151	Conjugation of Organoruthenium(II) 3-(1 <i>H</i> -Benzimidazol-2-yl)pyrazolo[3,4- <i>b</i>]pyridines and Indolo[3,2- <i>d</i>]benzazepines to Recombinant Human Serum Albumin: a Strategy To Enhance Cytotoxicity in Cancer Cells. <i>Inorganic Chemistry</i> , 2011, 50, 12669-12679.	4.6	56
152	Multinuclear Cytotoxic Metallodrugs: Physicochemical Characterization and Biological Properties of Novel Heteronuclear Gold-Titanium Complexes. <i>Inorganic Chemistry</i> , 2011, 50, 9472-9480.	4.6	85
153	Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3895-3902.	5.6	237
154	Metal-Based Inhibition of Poly(ADP-ribose) Polymerase ~ The Guardian Angel of DNA. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2196-2206.	5.6	144
155	Thiolato gold(I) complexes containing water-soluble phosphane ligands: a characterization of their chemical and biological properties. <i>Dalton Transactions</i> , 2011, 40, 10927.	3.0	55
156	Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. <i>Metallomics</i> , 2011, 3, 1318.	2.6	30
157	Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. <i>Dalton Transactions</i> , 2011, 40, 2006.	3.0	29
158	Organometallic ruthenium-based antitumor compounds with novel modes of action. <i>Journal of Organometallic Chemistry</i> , 2011, 696, 989-998.	2.1	344
159	Ruthenium(II) arene complexes with oligocationic triarylphosphine ligands: Synthesis, DNA interactions and in vitro properties. <i>Journal of Organometallic Chemistry</i> , 2011, 696, 1108-1116.	2.1	18
160	Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2647-2660.	3.0	190
161	Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid-142: An AFM Study. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1323-1329.	2.6	86
162	Anticancer Therapeutics That Target Selenoenzymes: Synthesis, Characterization, in vitro Cytotoxicity, and Thioredoxin Reductase Inhibition of a Series of Gold(I) Complexes Containing Hydrophilic Phosphine Ligands. <i>ChemMedChem</i> , 2010, 5, 96-102.	3.1	121

#	ARTICLE	IF	PR CITATIONS
163	Proteins as Possible Targets for Cytotoxic <i>trans</i> -Platinum(II) Complexes with Aliphatic Amine Ligands: Further Exceptions to the DNA Paradigm. <i>ChemMedChem</i> , 2010, 5, 1335-1343.	3.1	25
164	Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. <i>Medicinal Research Reviews</i> , 2010, 30, 550-580.	13.8	476
165	<i>trans</i> - <i>cis</i> - <i>cis</i> -[RuCl ₂ (DMSO) ₂ (2-amino-5-methyl-thiazole) ₂], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 111-117.	3.0	16
166	Anticancer activity of new organo-ruthenium, rhodium and iridium complexes containing the 2-(pyridine-2-yl)thiazole N,N-chelating ligand. <i>Journal of Organometallic Chemistry</i> , 2010, 695, 1119-1125.	2.1	125
167	Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS. <i>Journal of Analytical Atomic Spectrometry</i> , 2010, 25, 305.	3.1	98
168	Antiproliferative Activity of Gold(I) Alkyne Complexes Containing Water-Soluble Phosphane Ligands. <i>Organometallics</i> , 2010, 29, 2596-2603.	2.9	102
169	Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel <i>trans</i> -Rule-Breaker <i>trans</i> -Iridoplatinum(II) Complex. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 381-385.	3.4	33
170	Synthesis, characterisation and biological properties of gold(III) compounds with modified bipyridine and bipyridylamine ligands. <i>Dalton Transactions</i> , 2010, 39, 2239.	3.0	84
171	Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT. <i>Dalton Transactions</i> , 2010, 39, 5556.	3.0	85
172	The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins. <i>ChemMedChem</i> , 2010, 5, 1989-1994.	3.1	44
173	[Au ₂ (phen) ₂ (Me) ₂]($\frac{1}{4}$ O) ₂ (PF ₆) ₂ , a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 336-339.	3.4	83
174	Development of Bimetallic Titanocene ⁺ Ruthenium ⁺ Arene Complexes As Anticancer Agents: Relationships between Structural and Biological Properties. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6923-6933.	5.6	97
175	Solution Behaviour and Biomolecular Interactions of Two Cytotoxic <i>trans</i> -Platinum(II) Complexes Bearing Aliphatic Amine Ligands. <i>Chemistry - A European Journal</i> , 2009, 15, 9139-9146.	3.4	23
176	Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 761-770.	2.5	105
177	Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 1139-1149.	2.5	128
178	Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 310-312.	3.0	31
179	Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. <i>Coordination Chemistry Reviews</i> , 2009, 253, 1692-1707.	23.2	571
180	Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action. <i>Metallomics</i> , 2009, 1, 434.	2.6	64

#	ARTICLE	IF	PR CITATIONS
181	Excellent correlation between cathepsin B inhibition and cytotoxicity for a series of palladacycles. Dalton Transactions, 2009, , 10731.	3.0	68
182	Clioquinol Decreases Amyloid- β Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 423-440.	2.6	121
183	Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis. Journal of Biological Inorganic Chemistry, 2008, 13, 755-764.	2.5	35
184	The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose-Derived Stem Cells, Taken as a Model. Chemistry and Biodiversity, 2008, 5, 1513-1520.	2.3	12
185	Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action. Journal of Inorganic Biochemistry, 2008, 102, 564-575.	3.0	264
186	Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies. Journal of Inorganic Biochemistry, 2008, 102, 995-1006.	3.0	84
187	Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: Relevance to antitumour activity. Journal of Inorganic Biochemistry, 2008, 102, 2136-2141.	3.0	63
188	New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects <i>in vitro</i> : Mechanistic and pharmacological implications. FEBS Letters, 2008, 582, 844-847.	2.7	161
189	Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds. Journal of Medicinal Chemistry, 2008, 51, 6773-6781.	5.6	269
190	Structural Characterization, Solution Studies, and DFT Calculations on a Series of Binuclear Gold(III) Oxo Complexes: Relationships to Biological Properties. Inorganic Chemistry, 2008, 47, 2368-2379.	4.6	105
191	Potential pathogenic role of β -amyloid β 42-aluminum complex in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2008, 40, 731-746.	2.7	79
192	A multi-technique approach to predicting the molecular structure of cuprizone in the gas phase and in the crystalline state. CrystEngComm, 2008, , .	2.4	2
193	Exploiting Soft and Hard X-Ray Absorption Spectroscopy to Characterize Metallodrug/Protein Interactions: the Binding of [<i>trans</i> -RuCl ₄ (Im)(dimethylsulfoxide)] [ImH] (Im =) Tj ETQq 1 1 0.7843d 4 rgBT50Overlo		
194	Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity. Natural Product Communications, 2008, 3, .	0.6	9
195	Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. Journal of Analytical Atomic Spectrometry, 2007, 22, 960-967.	3.1	93
196	Insights into the Molecular Mechanisms of Protein Platination from a Case Study: The Reaction of Anticancer Platinum(II) Iminoethers with Horse Heart Cytochrome c. Biochemistry, 2007, 46, 12220-12230.	2.4	52
197	Antimalarial properties of green tea. Biochemical and Biophysical Research Communications, 2007, 353, 177-181.	2.1	68
198	ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chemical Communications, 2007, , 156-158.	3.4	142

#	ARTICLE	IF	PR CITATIONS
199	Unravelling the chemical nature of copper cuprizone. Dalton Transactions, 2007, , 2112.	3.0	57
200	New Copper(II)/Cyclic Tetrapeptide System That Easily Oxidizes to Copper(III) under Atmospheric Oxygen. Inorganic Chemistry, 2007, 46, 10038-10040.	4.6	29
201	fac-[Ru(CO) ₃] ²⁺ -Core Complexes and Design of Metal-Based Drugs. Synthesis, Structure, and Reactivity of Ru ^{II} Thiazole Derivative with Serum Proteins and Absorption/Release Studies with Acryloyl and Silica Hydrogels as Carriers in Physiological Media. Inorganic Chemistry, 2007, 46, 79-92.	4.6	38
202	Activity of Rat Cytosolic Thioredoxin Reductase Is Strongly Decreased by trans-[Bis(2-amino-5-ylidene)ethylenediamine] Ruthenium(II) Complex for a Ruthenium Compound. Journal of Medicinal Chemistry, 2007, 50, 5871-5874.	5.6	53
203	ESI-MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)-Arene PTA (RAPTA) Complexes. ChemMedChem, 2007, 2, 631-635.	3.1	88
204	DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery studied by circular dichroism and other biophysical techniques. Biophysical Chemistry, 2007, 127, 213-220.	2.1	38
205	Gold(III) compounds as anticancer drugs. Gold Bulletin, 2007, 40, 73-81.	0.8	137
206	Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c. Journal of Biological Inorganic Chemistry, 2007, 12, 1107-1117.	2.5	49
207	Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands. Journal of Medicinal Chemistry, 2006, 49, 5524-5531.	5.6	191
208	The reaction of artemisinins with hemoglobin: A unified picture. Bioorganic and Medicinal Chemistry, 2006, 14, 2972-2977.	2.6	66
209	Structural Investigation of Cisplatin-Protein Interactions: Selective Platination of His19 in a Cuprozinic Superoxide Dismutase. Angewandte Chemie - International Edition, 2006, 45, 1267-1269.	14.4	107
210	Exploring Metalloprotein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c. ChemMedChem, 2006, 1, 413-417.	3.1	92
211	Structural Investigation of Cisplatin-Protein Interactions: Selective Platination of His19 in a Cuprozinic Superoxide Dismutase. Angewandte Chemie, 2006, 118, 1289-1291.	1.4	5
212	Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1937-1942.	2.1	41
213	Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2315-2320.	2.1	186
214	Carbonic anhydrase inhibitors: Design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3821-3827.	2.1	28
215	Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 211-217.	5.2	21
216	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition of Cytosolic/Membrane-Associated Carbonic Anhydrase Isozymes I, II, and IX with Sulfonamides Incorporating Hydrazino Moieties. Journal of Medicinal Chemistry, 2005, 48, 2121-2125.	5.6	72

#	ARTICLE	IF	PR CITATIONS
217	Characterization of CA XIII, a Novel Member of the Carbonic Anhydrase Isozyme Family. <i>Journal of Biological Chemistry</i> , 2004, 279, 2719-2727.	2.2	227
218	COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2004, 4, 625-632.	2.6	138
219	Designing of Novel Carbonic Anhydrase Inhibitors and Activators. <i>Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2004, 2, 49-68.	1.2	141
220	New Developments on Thromboxane and Prostacyclin Modulators Part I: Thromboxane Modulators. <i>Current Medicinal Chemistry</i> , 2004, 11, 1223-1241.	2.6	78
221	Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 217-223.	2.1	261
222	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 231-234.	2.1	149
223	Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 6001-6006.	2.1	86
224	Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-1- β -D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 225-229.	2.1	70
225	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 337-341.	2.1	73
226	Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 869-873.	2.1	152
227	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2357-2361.	2.1	49
228	Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3757-3762.	2.1	38
229	Carbonic Anhydrase Inhibitors: Aliphatic N-phosphorylated Sulfamates--A Novel Zinc-anchoring Group Leading to Nanomolar Inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2004, 19, 275-278.	5.2	11
230	Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib: A New Pharmacological Opportunities Due to Related Binding Site Recognition. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 550-557.	5.6	443
231	Carbonic Anhydrase Inhibitors: Synthesis and Topical Intraocular Pressure Lowering Effects of Fluorine-Containing Inhibitors Devoid of Enhanced Reactivity. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2796-2804.	5.6	39
232	Carbonic Anhydrase Inhibitors: The First On-Resin Screening of a 4-Sulfamoylphenylthiourea Library. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5224-5229.	5.6	48
233	Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. <i>FEBS Letters</i> , 2004, 577, 439-445.	2.7	647
234	Carbonic anhydrase inhibitors. <i>Medicinal Research Reviews</i> , 2003, 23, 146-189.	13.8	1,188

#	ARTICLE	IF	PR CITATIONS
235	Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents. <i>Medicinal Research Reviews</i> , 2003, 23, 535-558.	13.8	428
236	Carbonic anhydrase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 837-840.	2.1	85
237	Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 841-845.	2.1	228
238	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2765-2768.	2.1	31
239	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamide—two heads are better than one?. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2759-2763.	2.1	36
240	Carbonic anhydrase inhibitors: Topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzamide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2867-2873.	2.1	34
241	Predicting bone mineral density of postmenopausal healthy and cirrhotic Italian women using anthropometric variables. <i>Digestive and Liver Disease</i> , 2003, 35, 881-887.	2.4	7
242	Carbonic Anhydrase Inhibitors: Inhibition of Transmembrane, Tumor-Associated Isozyme IX, and Cytosolic Isozymes I and II with Aliphatic Sulfamates. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5471-5477.	5.6	79
243	Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2197-2204.	5.6	141
244	Carbonic Anhydrase Inhibitors: X-ray Crystallographic Structure of the Adduct of Human Isozyme II with the Perfluorobenzoyl Analogue of Methazolamide. Implications for the Drug Design of Fluorinated Inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 303-308.	5.2	50
245	Targeting Cysteine Residues of Biomolecules: New Approaches for the Design of Antiviral and Anticancer Drugs. <i>Current Medicinal Chemistry</i> , 2002, 9, 1167-1185.	2.6	56
246	Sulfonamides and Sulfonylated Derivatives as Anticancer Agents. <i>Current Cancer Drug Targets</i> , 2002, 2, 55-75.	2.5	276
247	Carbonic Anhydrase Inhibitors With Strong Topical Antiglaucoma Properties Incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide Scaffold. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2002, 17, 9-18.	5.2	15
248	Carbonic Anhydrase Inhibitors: Synthesis of Water Soluble Sulfonamides Incorporating a 4-sulfamoylphenylmethylthiourea Scaffold, with Potent Intraocular Pressure Lowering Properties. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2002, 17, 333-343.	5.2	35
249	Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs.. <i>Environmental Health Perspectives</i> , 2002, 110, 801-806.	8.8	34
250	Cyclodextrin Complexes of Sulfonamide Carbonic Anhydrase Inhibitors As Long-Acting Topically Acting Antiglaucoma Agents. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2211-2219.	3.2	17
251	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition Against Isozymes I, II and IV of Topically Acting Antiglaucoma Sulfonamides Incorporating <i>cis</i> -5-Norbornene-3-Carboxy-2-Carboxamido Moieties. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2001, 16, 113-123.	0.5	8
252	Interactions of two cytotoxic organotin(IV) compounds with calf thymus DNA. <i>Journal of Inorganic Biochemistry</i> , 2001, 85, 297-300.	3.0	52

#	ARTICLE	IF	PR CITATIONS
253	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1787-1791.	2.1	62
254	Synthesis, molecular structure and solution chemistry of the iridium(III) complex imidazolium [trans(bisimidazole)tetrachloro iridate(III)] (IRIM). <i>Inorganica Chimica Acta</i> , 2001, 312, 74-80.	2.8	40
255	Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. <i>Bioorganic and Medicinal Chemistry</i> , 2000, 8, 2145-2155.	2.6	68
256	Effects of two representative antitumor ruthenium(III) complexes on thermal denaturation profiles of DNA. <i>Inorganica Chimica Acta</i> , 2000, 303, 283-286.	2.8	21
257	DNA as a Possible Target for Antitumor Ruthenium(III) Complexes. <i>Archives of Biochemistry and Biophysics</i> , 2000, 376, 156-162.	2.9	117
258	Formation of Supramolecular Structures between DNA and Starburst Dendrimers Studied by EPR, CD, UV, and Melting Profiles. <i>Macromolecules</i> , 2000, 33, 7842-7851.	5.0	125
259	Carbonic Anhydrase Inhibitors: Water-Soluble 4-Sulfamoylphenylthioureas as Topical Intraocular Pressure-Lowering Agents with Long-Lasting Effects. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4884-4892.	5.6	145